Garsorasib Company Today announced a significant milestone in the development of its flagship drug, Garsorasib, a novel KRAS G12C inhibitor designed to treat non-small cell lung cancer (NSCLC) and other solid tumors. This groundbreaking therapy has…
Zevorcabtagene Autoleucel is a CAR-T cell therapy targeting B-cell maturation antigen (BCMA) by genetically engineering a patient’s own T cells to precisely recognize and kill multiple myeloma cells that express BCMA, a marker highly expressed…
Taletrectinib Adipate Capsules have been approved by the China National Drug Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received prior ROS1…
In the ever-evolving field of oncology, the development of targeted therapies has revolutionized the way we approach cancer treatment. One such advancement is the emergence of Welireg (belzutifan), a novel therapeutic agent that has shown promise…
Parkinson’s Disease (PD) is a complex neurodegenerative disease that affects the quality of life of millions of patients worldwide. In recent years, as medical research continues to deepen, the emergence of a new drug, Xadago…
Pretomanid 200 mg tablets are a novel nitroimidazooxazine-based anti-tuberculosis drug that kills Mycobacterium tuberculosis by inhibiting mycobacterial cell wall synthesis. Its unique dual mechanism of action makes it an excellent candidate for drug-resistant TB. Based…
Introduction Izervay (Avacincaptad Pegol) is a groundbreaking treatment approved for geographic atrophy (GA), an advanced stage of age-related macular degeneration (AMD). GA is a leading cause of vision loss in older adults, with no prior…
Jazz Pharmaceuticals recently announced that its anticancer drug Zepzelca (Lurbinectedin Injection) in combination with Atezolizumab (Tecentriq) achieved significant overall survival (OS) and progression-free survival (PFS) improvements in the first-line maintenance treatment of extensive-stage small cell…
Japanese pharmaceutical company Fuji Yakuhin Co., Ltd. announced that Urece Tablet (Dotinurad Tablet), a novel uric acid-lowering drug developed by the company, has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and is…
Leqembi was recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2024 for the treatment of early-stage Alzheimer’s disease, targeting patients with mild cognitive impairment…
Sodium phenylbutyrate is a salt derivative of 4-phenylbutyrate (4-PBA), an aromatic fatty acid with unique metabolic properties. It plays a crucial role in the treatment of urea cycle disorders (UCDs) by facilitating an alternative pathway…
Guangzhou, China, October 15, 2023 – Ivonescimab Akeso (Kangfang Bio, HKEX: 9926.HK) today announced the latest clinical trial of its self-developed bispecific antibody drug Ivonescimab(R&D code: AK112). The drug has demonstrated significant anti-tumor activity in…
